IXA4 Induces Antigen Cross-Presentation in Murine Mesenchymal Stromal Cells and Supports Melanoma Vaccination
Abstract Background Antigen cross-presentation is a key function for cell-based cancer vaccination. Mesenchymal stromal cells (MSCs) provide an experimentally tractable platform, but the cellular states that permit efficient presentation of exogenous proteins remain incompletely defined. We investigated whether IXA4, a pharmacological activator of IRE1α-associated signaling, induces cross-presentation and supports MSC-based melanoma vaccination. Methods Primary murine bone-marrow-derived MSCs were conditioned with IXA compounds and assessed using ovalbumin-dependent B3Z reporter assays, flow cytometry, secretome profiling, and RNA sequencing. Pathway inhibitors and Xbp1 perturbations were used to examine signaling contributions. Tumor lysate-loaded, IXA4-reprogrammed MSCs (IRM-4 cells) were evaluated in B16F0-bearing mice, alone or with programmed cell death protein 1 (PD-1) blockade. Results IXA4 induced ovalbumin-dependent reporter activation at a tolerated working concentration of 5 µM. The response was sensitive to IRE1 RNase inhibition and accompanied by increased surface H2-Kᵇ, altered soluble mediator composition, and transcriptional remodeling of endoplasmic reticulum proteostasis and vesicular trafficking. No clear increases were detected in the bulk antigen-handling or oxidant-sensitive assays examined. IRM-4 vaccination delayed melanoma progression, with the most sustained benefit observed alongside PD-1 blockade. Responsiveness varied among MSC preparations and was associated with baseline unfolded protein response programs. Xbp1 -edited cells retained an IXA4-associated response, whereas enforced XBP1s expression did not reproduce the cross-presentation phenotype. Conclusions IXA4 conditioning supports functional antigen cross-presentation and experimental MSC-based melanoma vaccination. The dependence of this response on the starting cellular state, rather than XBP1s abundance alone, identifies functional potency testing and mechanistic validation as priorities for further development.
Authors
- Jean‐Pierre Bikorimana
- Malak Lahrichi
- Moutih Rafei (ORCID: https://orcid.org/0000-0003-4457-1350)
- Sébastien Talbot (ORCID: https://orcid.org/0000-0001-9932-7174)
- Jamilah Abusarah (ORCID: https://orcid.org/0000-0003-4353-5585)
- Nehmé El-Hachem (ORCID: https://orcid.org/0000-0002-5778-5342)
- Roudy Farah (ORCID: https://orcid.org/0009-0001-6232-3388)
- Yasmine Adda-Bouchard (ORCID: https://orcid.org/0009-0003-7713-4568)
- Perla Matar
- Abba Cissé (ORCID: https://orcid.org/0009-0006-4250-3679)
Institutions
- Queen's University (CA)
- Queens University (BD)
- Lebanese American University (LB)
- Université de Montréal (CA)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-13
- DOI
- https://doi.org/10.21203/rs.3.rs-11318856/v1
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- preprint
Funders
- Canadian Institutes of Health Research